AlloVir, Inc.
NASDAQ: ALVR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vikas Sinha CPA,
- Employees
- 6
- Headquarters
- Waltham, United States
- IPO year
- 2020
- Market cap
- $49.5M
- Website
- https://www.allovir.com
Loading ALVR…
Loading profile data…Frequently asked questions about ALVR
What does AlloVir, Inc. (ALVR) do?
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy de...
Where does ALVR trade?
AlloVir, Inc. (ALVR) trades on the NASDAQ Global Select.
What sector is ALVR in?
AlloVir, Inc. (ALVR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of AlloVir, Inc.?
Vikas Sinha CPA, is the chief executive officer of AlloVir, Inc. (ALVR).
Where is AlloVir, Inc. headquartered?
AlloVir, Inc. is headquartered in United States.
Does ALVR pay a dividend?
AlloVir, Inc. (ALVR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALVR go public?
AlloVir, Inc. (ALVR) completed its initial public offering in 2020.